Water Tower Research

iCrowdNewswire   Feb 9, 2021  9:30 AM ET

The Fireside Chat will take place on Wednesday, February 10th at 2:00 pm Eastern Time. The live event will also be archived and available for replay. The Fireside Chat is open for all investors to access.

“We are excited to host the CEO and CMO from Theratechnologies Inc. following the FDA fast-track designation announced by the company on February 4, 2021 for its lead peptide-drug conjugate TH1902. This designation is a significant milestone for the company’s oncology platform and its proprietary SORT1+ Technology,” said Thierry Wuilloud, Managing Director at Water Tower Research. Theratechnologies has been successful in treating HIV-associated disease with EGRIFTA, EGRIFTA SV, and Trogarzo and has Tesamorelin F8 in the development pipeline. TH1902 marks the company’s expansion into anti-cancer therapies. The Phase 1 trial is expected to commence in the 2021 second quarter and is designed to identify the recommended dose for Phase 2 development.

Mr. Wuilloud continued, “The company’s proprietary technology has a major advantage over traditional chemotherapy given that it is less toxic, more targeted, and allows for higher drug concentration. As a result, TH1902 can potentially be used for such cancers as colorectal, pancreatic, ovarian and triple negative breast cancer. This new technology could make a meaningful contribution in the fight against cancer as it could offer patients a less toxic and more successful path to fighting the disease.”

Register for the Event HERE.

Contact Information:

Thierry Wuilloud, CFA
Managing Director
Special Situations
Water Tower Research LLC
+1.503.801.7755
www.watertowerresearch.com


iCrowdNewswire

Keywords:    Cancer drugs,Biotech,FDAapproval,Oncology,HIV treatments or HIV therapies,Breast cancer,Cancer,Equity research, Capital markets, Investor relations , HLS.TO,MDP.TO,GUD.TO,RX.TO